Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494918 | 1.00 | TACR1 (0.40) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL6052769 | 0.93 | TACR1 (0.38) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL3141190 | 0.93 | TACR1 (0.38) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL2675548 | 0.93 | TACR1 (0.38) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL7835398 | 0.93 | TACR1 (0.38) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL7528040 | 0.93 | TACR1 (0.38) | TACR1SIRT1AGTR2DPP4FUCA1 | |
| SCHEMBL6053036 | 0.88 | TACR1 (0.48) | TACR1SIRT1DPP4ACEFAP | |
| SCHEMBL7531133 | 0.86 | TACR1 (0.44) | TACR1DPP4ACEFAPDPP8 | |
| SCHEMBL6704820 | 0.79 | TACR1 (0.38) | TACR1SIRT1DPP4FUCA1FAP | |
| SCHEMBL3094922 | 0.79 | TACR1 (0.38) | TACR1SIRT1DPP4FUCA1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | claimed |
| US-6555569-B2 | Especially for treatment of Chlamydia pneumoniae | PFIZER INC. | 2003-04-29 | — | — | US | claimed |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PFIZER PRODUCTS INC. | 2002-09-05 | — | — | US | claimed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | claimed |
| EP-1177791-A2 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20010046985-A1 | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | SUTCLIFFE JOYCE A (US) | 2001-11-29 | — | — | US | claimed |
| EP-1149580-A1 | Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1061074-A1 | Novel process and intermediates | Pfizer Products Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046985-A1 | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | PYGL, PYGM, PYGB | TACR1 4321/4885SIRT1 1143/4885AGTR2 2560/4885 |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | TACR1 1639/4885SIRT1 802/4885AGTR2 452/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | TACR1 1523/4885SIRT1 667/4885AGTR2 363/4885 |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PYGL, PYGM, G6PC1 | TACR1 4450/4885SIRT1 2564/4885AGTR2 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.